Fulcrum Therapeutics (FULC)Siren, L.L.C. added to its stake +400K shares

2.35M

Shares reported · +400K vs prior quarter

0.50%

Disclosed portfolio weight

$18M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 23, 2026Company filing · Form 8-K · Agreement ended, ResultsChanged a top executive or board member, and ended an important agreement (and 1 more item)“On April 23, 2026, the board of directors, or the Board, of Fulcrum, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Josh Lehrer as a member of the Board, with immediate effect.”

What came next

1. May 31, 2026Company filing · Form 8-K · Restructuring, Other newsAnnounced job cuts, closures or a restructuring, and reported other company news“On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD.”
2. Jun 5, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously disclosed, on May 31, 2026, the board of directors, or Board, of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease.”
3. Aug 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously disclosed in a current report on Form 8-K filed on June 11, 2026, Greg Tourangeau, Vice President, Finance and principal accounting officer of Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed with Fulcrum that Mr. Tourangeau will depart from his position at Fulcrum on a date to be agreed.”
4. Aug 16, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesControl of the company changed hands, and changed a top executive or board member (and 3 more items)“On August 17, 2026, Fulcrum and Slate issued a joint press release announcing the execution of the Merger Agreement and the Purchase Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference.”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Fulcrum Therapeutics

For Fulcrum Therapeutics, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its FULC page.

How this filing works

• SEC Form 13F

Other disclosures at Fulcrum Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 13, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 13, 2026

Everything OQRO holds on this company is on its FULC page.